| Literature DB >> 36004276 |
Akari Kaga1, Tetsuya Ikeda1, Keisei Tachibana2, Ryota Tanaka2, Haruhiko Kondo2, Takanori Kawabata3, Tomoko Yorozu4, Koichiro Saito5.
Abstract
Background: Numerous studies have shown that improving oral hygiene contributes to a reduction in the risk of postoperative complications in patients with head and neck cancer, cardiac disease, and esophageal cancer. However, the beneficial standard for oral management procedures during the perioperative period has not yet been established. Therefore, our aim was to determine whether or not their innovative oral management intervention contributed to a reduction in postoperative complications in lung cancer.Entities:
Keywords: C-D, Clavian-Dindo; ECOG, Eastern Cooperative Oncology Group; PS, performance status; hospital stay period; lung cancer surgery; oral management; oral stimulation; postoperative complications
Year: 2022 PMID: 36004276 PMCID: PMC9390213 DOI: 10.1016/j.xjon.2022.01.021
Source DB: PubMed Journal: JTCVS Open ISSN: 2666-2736
Figure 1The 2 groups in this study. The intervention group had full oral assessment by dentists and dental hygienists at Kyorin University Hospital before general anesthesia lung cancer surgery between April 2016 and March 2018. The nonintervention group had no oral assessment and lung cancer surgery between April 2014 and March 2016. The study was limited to lung cancer patients who had lobectomy and pneumonectomy.
Figure 2Oral mucosa stimulation with toothbrush. 1, Gum. 2, Right buccal mucosa. 3, Left buccal mucosa.
Figure 3Subjects were divided into 2 groups. Patients with no oral management intervention who underwent surgery from April 2014 to March 2016 and patients with our oral management intervention who underwent surgery from April 2016 to March 2018. All patients from April 2016 had our oral management intervention. Patients were instructed on how to stimulate oral mucosa with a toothbrush. Our oral management intervention reduced the number of postoperative complications from pneumonia, hospital stay, and Clavian-Dindo classification Ⅱ and greater.
Patient characteristics and surgical information
| Characteristic | Oral management group (n = 164) | No oral management group (n = 199) | |
|---|---|---|---|
| Gender | |||
| Male | 114 (69.5) | 123 (61.8) | .150 |
| Female | 50 (30.5) | 76 (38.2) | |
| Age (y) | 69 (30-91) | 69 (38-90) | .768 |
| Body mass index | 22.75 (16.19-32.71) | 22.75 (0.00-42.31) | .663 |
| ECOG performance status | |||
| 0 | 155 (94.5) | 171 (85.9) | .008 |
| 1 | 9 (5.5) | 28 (14.1) | |
| %VC | 103.40 (24.30-1306.00) | 108.40 (42.50-153.50) | .012 |
| %FEV1 | 73.30 (45.90-717.00) | 74.20 (27.10-708.00) | .202 |
| Comobidities | |||
| Artificial dialysis | 1 (0.6) | 1 (0.5) | 1.000 |
| Interstitial pneumonia | 2 (1.2) | 3 (1.5) | 1.000 |
| Ischemic cardiac disease | 4 (2.4) | 13 (6.7) | .080 |
| Cranial nerve disease or cerebrovascular disorder | 4 (2.4) | 11 (5.6) | .186 |
| Diabetes mellitus | 22 (13.4%) | 29 (14.9) | .762 |
| Autoimmune disorder | 2 (1.2%) | 1 (0.5) | .594 |
| Arrhythmia (medical treatment) | 6 (3.7) | 6 (3.1) | .777 |
| Hypertension | 49 (29.9) | 9 (4.6) | <.001 |
| Smoking status | |||
| Never smoked | 42 (39.3) | 65 (60.7) | .301 |
| Quit ≥30 d before surgery/exsmoker | 103 (47.0) | 116 (53.0) | |
| Quit <30 d before surgery/still smoking | 19 (51.4) | 18 (48.6) | |
| Preoperative therapy | 1 (0.6) | 4 (2.0) | .383 |
| Size of tumor (cm) | 2.90 (0.90-9.20) | 2.50 (0.80-9.10) | .001 |
| Side | |||
| Right | 112 (68.3) | 132 (66.3) | .737 |
| Left | 52 (31.7) | 67 (33.7) | |
| Albumin (g/dL) | 4.20 (2.60-5.00) | 4.30 (2.50-5.20) | .017 |
Values are presented as median (min-max) or n (%). ECOG, Eastern Cooperative Oncology Group; %VC, vital capacity; %FEV1, forced expiratory volume for 1 second expressed as a percentage of the forced vital capacity.
P < .05.
Clinical outcome and surgical related information
| Variable | Oral management group (n = 164) | No management group (n = 199) | |
|---|---|---|---|
| Operation time (min) | 238.5 (99.0-598.0) | 209.0 (90.0-515.0) | <.001 |
| Blood loss (mL) | 29.5 (0-6162) | 39 (2-811) | .032 |
| Surgical approach | |||
| VATS | 156 (95.1) | 195 (98.0) | .149 |
| Thoracotomy | 8 (4.9) | 4 (2.0) | |
| Histologic type | |||
| Adenocarcinoma | 112 (68.3) | 145 (72.9) | .355 |
| Nondenocarcinoma | 52 (31.7) | 54 (27.1) | |
| Pathologic staging | |||
| 0 | 4 (2.4) | 6 (3.0) | <.001 |
| IA and IB | 70 (42.7) | 122 (61.3) | |
| IIA and IIB | 40 (24.4) | 42 (21.1) | |
| IIIA and IIIB | 37 (22.6) | 28 (14.1) | |
| IV | 13 (7.9) | 1 (0.5) | |
| Clavian-Dindo classification | 31 (18.9) | 59 (29.6) | .020 |
| Postoperative pneumonia | 3 (1.8) | 19 (9.6) | .002 |
| Postoperative hospital stay | 8 (2-113) | 9 (4-89) | .029 |
Values are presented as median (min-max) or n (%).VATS, Video-assisted thoracoscopic surgery.
P < .05.
Association with postoperative pneumonia (n = 363)
| Variable | Univariate | Multivariate | ||
|---|---|---|---|---|
| Odds ratio (95% CI) | Odds ratio (95% CI) | |||
| Oral management | ||||
| No | 1 | – | 1 | – |
| Yes | 0.177 (0.041-0.530) | 0.006 | 0.184 (0.042-0.571) | .009 |
| Gender | ||||
| Male | 1 | – | ||
| Female | 0.535 (0.172-1.390) | .230 | ||
| Age (y) | 1.050 (0.998-1.110) | .074 | ||
| Body mass index | 1.033 (0.918-1.155) | .583 | ||
| ECOG performance status | ||||
| 0 | 1 | – | 1 | – |
| 1 | 4.838 (1.734-12.459) | .001 | 2.883 (0.927-8.127) | .053 |
| %VC | 0.996 (0.972-1.004) | .738 | ||
| %FEV1 | 0.971 (0.935-1.002) | .130 | ||
| Comorbidities | ||||
| Artificial dialysis | 0.000 (0-∞) | .990 | ||
| Interstitial pneumonia | 0.000 (0-∞) | .990 | ||
| Ischemic cardiac disease | 2.267 (0.342-8.849) | .300 | ||
| Cranial nerve disease or cerebrovascular disorder | 1.157 (0.062-6.221) | .891 | ||
| Diabetes mellitus | 1.984 (0.625-5.345) | .202 | ||
| Autoimmune disorder | 8.400 (0.381-91.360) | .088 | ||
| Arrhythmia (medical treatment) | 1.486 (0.079-8.239) | .711 | ||
| Hypertension | 0.530 (0.083-1.896) | .402 | ||
| Smoking status | ||||
| Never smoked | 1 (ref) | – | ||
| Quit ≥30 d before surgery/exsmoker | 2.030 (0.723-7.222) | .216 | ||
| Quit <30 d before surgery/still smoking | 1.471 (0.198-7.881) | .664 | ||
| Preoperative therapy | ||||
| No | 1 (ref) | – | ||
| Yes | 0.000 (-∞) | .990 | ||
| Size of tumor (cm) | 1.148 (0.868-1.466) | .297 | ||
| Surgical side | ||||
| Right | 1 | – | ||
| Left | 0.586 (0.189-1.523) | .305 | ||
| Operation time (min) | 1.002 (0.996-1.007) | .577 | ||
| Blood loss (mL) | 1.000 (0.998-1.001) | .799 | ||
| Surgical approach | ||||
| Thoracotomy | 1 | – | ||
| VATS | 2.845E+6 (0-) | .990 | ||
| Histologic type | ||||
| Adenocarcinoma | 1 | – | 1 | – |
| Nonadenocarcinoma | 2.589 (1.075-6.242) | .032 | 2.221 (0.852-5.708) | .096 |
| Pathologic staging | ||||
| 0 | 1 | – | ||
| IA and IB | 1.610E+6 (0-) | .991 | ||
| IIA and IIB | 5.245E+6 (0-) | .990 | ||
| IIIA and IIIB | 3.545E+6 (0-) | .990 | ||
| IV | 3.273E+6 (0-) | .990 | ||
| Albumin (g/dL) | 0.397 (0.175-0.951) | .030 | 0.562 (0.231-1.404) | .208 |
ECOG, Eastern Cooperative Oncology Group; %VC, vital capacity; %FEV1, forced expiratory volume for 1 second expressed as a percentage of the forced vital capacity; VATS, video-assisted thoracoscopic surgery.
Number of events = 22.
Reference category.
P < .05.
An extremely large or near-zero odds ratio is due to the small number of postoperative pneumonia events (known as the complete separation).
Association with postoperative hospital stay (n = 363)
| Variable | Univariate | Multivariate | ||
|---|---|---|---|---|
| Relative risk (95% CI) | Relative risk (95% CI) | |||
| Oral management | ||||
| No | 1 | 1 | ||
| Yes | 0.810 (0.712-0.920) | .001 | 0.725 (0.645-0.815) | <.001 |
| Gender | ||||
| Male | 1 | – | 1 | – |
| Female | 0.810 (0.708-0.928) | .002 | 1.063 (0.921-1.228) | .401 |
| Age (y) | 1.004 (0.997-1.011) | .257 | ||
| Body mass index | 0.996 (0.979-1.014) | .644 | ||
| ECOG performance status | ||||
| 0 | 1 | – | 1 | – |
| 1 | 1.416 (1.159-1.743) | .001 | 1.246 (1.033-1.507) | .022 |
| %VC | 0.999 (0.998-1.0002) | .148 | ||
| %FEV1 | 0.999 (0.998-1.001) | .288 | ||
| Comorbidities | ||||
| Artificial dialysis | 1.097 (0.493-2.831) | .833 | ||
| Interstitial pneumonia | 0.961 (0.566-1.725) | .888 | ||
| Ischemic cardiac disease | 1.070 (0.797-1.460) | .659 | ||
| Cranial nerve disease or cerebrovascular disorder | 1.334 (0.984-1.844) | .071 | ||
| Diabetes mellitus | 1.193 (0.997-1.434) | .057 | ||
| Autoimmune disorder | 1.211 (0.630-2.575) | .589 | ||
| Arrhythmia (medical treatment) | 1.225 (0.871-1.765) | .258 | ||
| Hypertension | 1.001 (0.842-1.195) | .993 | ||
| Smoking status | ||||
| Never smoked | 1 | – | 1 | – |
| Quit ≥30 d before surgery/exsmoker | 1.486 (1.288-1.714) | .001 | 1.241 (1.059-1.454) | .007 |
| Quit <30 d before surgery/still smoking | 1.373 (1.096-1.729) | .006 | 1.094 (0.867-1.378) | .436 |
| Preoperative therapy | ||||
| No | 1 | – | ||
| Yes | 0.737 (0.425-1.343) | .295 | ||
| Size of tumor (cm) | 1.123 (1.078-1.171) | <.001 | 1.053 (1.010-1.099) | .013 |
| Surgical side | ||||
| Right | 1 | – | ||
| Left | 0.880 (0.768, 1.010) | .069 | ||
| Operation time (min) | 1.0026 (1.0018-1.0033) | <.001 | 1.002 (1.001-1.003) | <.001 |
| Blood loss (mL) | 1.0007 (1.0004-0.0010) | <.001 | 1.0002 (1.0001-1.0004) | .009 |
| Surgical approach | ||||
| Thoracotomy | 1 | – | 1 | – |
| VATS | 0.456 (0.324-0.625) | <.001 | 0.700 (0.502-0.958) | .025 |
| Histologic type | ||||
| Adenocarcinoma | 1 | – | 1 | – |
| Nonadenocarcinoma | 1.313 (1.145-1.508) | <.001 | 1.037 (0.909-1.183) | .589 |
| Pathologic staging | ||||
| 0 | 1 | – | 1 | – |
| IA and IB | 1.135 (0.758-1.667) | .529 | 0.953 (0.667-1.351) | .789 |
| IIA and IIB | 1.573 (1.040-2.337) | .028 | 1.158 (0.797-1.669) | .434 |
| IIIA and IIIB | 1.827 (1.203-2.728) | .004 | 1.125 (0.765-1.642) | .542 |
| IV | 1.080 (0.652-1.777) | .764 | 0.812 (0.740-0.967) | .377 |
| Albumin (g/dL) | 0.675 (0.589-0.775) | <.001 | 0.847 (0.740-0.967) | .014 |
ECOG, Eastern Cooperative Oncology Group; VC, vital capacity; %FEV1, forced expiratory volume for 1 second expressed as a percentage of the forced vital capacity; VATS, video-assisted thoracoscopic surgery.
Reference category.
P < .05.
Association of postoperative complications with Clavian-Dindo classification (n = 363)
| Variable | Univariate | Multivariate | ||
|---|---|---|---|---|
| Odds ratio (95% CI) | Odds ratio (95% CI) | |||
| Oral management | ||||
| No | 1 | 1 | ||
| Yes | 0.553 (0.334-0.902) | .019 | 0.503 (0.298-0.835) | .009 |
| Gender | ||||
| Male | 1 | – | ||
| Female | 0.753 (0.445-1.249) | .280 | ||
| Age (y) | 1.024 (0.998-1.053) | .080 | ||
| Body mass index | 0.959 (0.894-1.025) | .224 | ||
| ECOG performance status | ||||
| 0 | 1 | – | ||
| 1 | 1.752 (0.830-3.556) | .128 | ||
| %VC | 0.999 (0.991-1.003) | .788 | ||
| %FEV1 | 1.001 (0.995-1.005) | .766 | ||
| Comorbidities | ||||
| Artificial dialysis | 3.103 (0.122-79.033) | .425 | ||
| Interstitial pneumonia | 0.767 (0.039-5.272) | .814 | ||
| Ischemic cardiac disease | 1.300 (0.404-3.618) | .631 | ||
| Cranial nerve disease or cerebrovascular disorder | 1.126 (0.306-3.389) | .843 | ||
| Diabetes mellitus | 1.498 (0.768-2.825) | .221 | ||
| Autoimmune disorder | 6.279 (0.595-136.093) | .136 | ||
| Arrhythmia (medical treatment) | 1.027 (0.224-3.534) | .968 | ||
| Hypertension | 1.343 (0.704-2.475) | .355 | ||
| Smoking status | ||||
| Never smoked | 1 | – | 1 | – |
| Quit ≥30 d before surgery/exsmoker | 2.235 (1.258-4.150) | .008 | 2.153 (1.192-4.057) | .014 |
| Quit <30 d before surgery/still smoking | 1.460 (0.547-3.655) | .429 | 1.370 (0.497-3.537) | .526 |
| Preoperative therapy | ||||
| No | 1 | |||
| Yes | 0 (-,∞) | .982 | ||
| Size of tumor (cm) | 1.070 (0.911, 1.249) | .398 | ||
| Surgical side | ||||
| Right | 1 | – | ||
| Left | 0.843 (0.498-1.401) | .517 | ||
| Operation time (min) | 1.002 (0.999-1.005) | .134 | ||
| Blood loss (mL) | 1.003 (1.001-1.005) | .011 | 1.003 (1.001, 1.005) | .025 |
| Surgical approach | ||||
| Thoracotomy | 1 | – | ||
| VATS | 1.673 (0.431-11.020) | .512 | ||
| Histologic type | ||||
| Adenocarcinoma | 1 | – | ||
| Nonadenocarcinoma | 1.210 (0.717-2.013) | .468 | ||
| Pathologic staging | ||||
| 0 | 1 | – | ||
| IA and IB | 1.053 (0.252-7.156) | .950 | ||
| IIA and IIB | 2.189 (0.507-15.144) | .342 | ||
| IIIA.and.IIIB | 1.532 (0.343-10.796) | .611 | ||
| IV | 0.308 (0.013-3.722) | .366 | ||
| Albumin (g/dL) | 0.630 (0.370-1.076) | .087 | ||
ECOG, Eastern Cooperative Oncology Group; %VC, vital capacity; %FEV1, forced expiratory volume for 1 second expressed as a percentage of the forced vital capacity; VATS, video-assisted thoracoscopic surgery.
Number of events = 90.
Reference category.
P < .05.